Canaccord initiated coverage of Organigram (OGI) with a Buy rating and C$3 price target The firm says that despite regulatory headwinds and structural inefficiencies, the Canadian cannabis market “remains a global benchmark for legal cannabis commercialization.” Organigram is accelerating its transition a vertically integrated global cannabis company, with market leading positions including the number one share in pre-rolls, concentrates and milled flower, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGI:
- OGI Upcoming Earnings Report: What to Expect?
- Organigram Deepens Phylos Partnership to Secure Long-Term Cannabis Genetics Edge
- Organigram extends innovation investment in Phylos
- Organigram price target raised to C$4 from C$3.60 at Alliance Global
- Midday Fly By: Ford takes $19.5B EV writedown, Apple expanding iPhone lineup